Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 3

Behavior and neuropsychiatric manifestations in Angelman syndrome

Authors Karine Pelc, Guy Cheron, Bernard Dan

Published 6 June 2008 Volume 2008:4(3) Pages 577—584

DOI http://dx.doi.org/10.2147/NDT.S2749

Karine Pelc1, Guy Cheron2, Bernard Dan1,2

1Department of Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium; 2Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles (ULB), Brussels, Belgium

Abstract: Angelman syndrome has been suggested as a disease model of neurogenetic developmental condition with a specific behavioral phenotype. It is due to lack of expression of the UBE3A gene, an imprinted gene located on chromosome 15q. Here we review the main features of this phenotype, characterized by happy demeanor with prominent smiling, poorly specific laughing and general exuberance, associated with hypermotor behavior, stereotypies, and reduced behavioral adaptive skills despite proactive social contact. All these phenotypic characteristics are currently difficult to quantify and have been subject to some differences in interpretation. For example, prevalence of autistic disorder is still debated. Many of these features may occur in other syndromic or nonsyndromic forms of severe intellectual disability, but their combination, with particularly prominent laughter and smiling may be specific of Angelman syndrome. Management of problematic behaviors is primarily based on behavioral approaches, though psychoactive medication (eg, neuroleptics or antidepressants) may be required.

Keywords: Angelman syndrome, UBE3A, chromosome 15, behavioral phenotypes, autism, neurogenetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain

Tamaru M, Akita H, Nakatani T, Kajimoto K, Sato Y, Hatakeyama H, Harashima H

International Journal of Nanomedicine 2014, 9:4267-4276

Published Date: 8 September 2014

Delivery of bone morphogenetic protein-2 and substance P using graphene oxide for bone regeneration

La WG, Jin M, Park S, Yoon HH, Jeong GJ, Bhang SH, Park H, Char K, Kim BS

International Journal of Nanomedicine 2014, 9:107-116

Published Date: 7 May 2014

Nanoscale drug delivery systems and the blood–brain barrier

Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D

International Journal of Nanomedicine 2014, 9:795-811

Published Date: 7 February 2014

Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention

Wang D, Taylor EW, Wang Y, Wan X, Zhang J

International Journal of Nanomedicine 2012, 7:1711-1721

Published Date: 29 March 2012

The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation

Santos-Martinez MJ, Inkielewicz-Stepniak I, Medina C, Rahme K, D'Arcy DM, Fox D, Holmes JD, Zhang H, Radomski MW

International Journal of Nanomedicine 2012, 7:243-255

Published Date: 13 January 2012

Bendamustine in the treatment of non-Hodgkin’s lymphomas

Fredrick Hagemeister, George Manoukian

OncoTargets and Therapy 2009, 2:269-279

Published Date: 4 December 2009

The evolving role of alemtuzumab (Campath-1H) in renal transplantation

Phuong-Thu T Pham, Gerald S Lipshutz, Phuong-Truc T Pham, Joseph Kawahji, Jennifer S Singer, Phuong-Chi T Pham

Drug Design, Development and Therapy 2009, 3:41-49

Published Date: 23 December 2008

Update on the use of pramipexole in the treatment of Parkinson’s disease

Radu Constantinescu

Neuropsychiatric Disease and Treatment 2008, 4:337-352

Published Date: 11 April 2008

Levetiracetam in the treatment of childhood epilepsy

James W Wheless

Neuropsychiatric Disease and Treatment 2007, 3:409-421

Published Date: 15 September 2007